Chemo-Pharma [CPL] vs Ashok Leyland [ASHOKLEY] Detailed Stock Comparison

Chemo-Pharma Laboratories Inc.

BSE
Loading...

Ashok Leyland Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Chemo-Pharma Laboratories Inc. wins in 12 metrics, Ashok Leyland Ltd. wins in 7 metrics, with 0 ties. Chemo-Pharma Laboratories Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Chemo-Pharma Laboratories Inc. Ashok Leyland Ltd. Better
P/E Ratio (TTM) 13.22 30.23 Chemo-Pharma Laboratories Inc.
Price-to-Book Ratio 2.69 7.91 Chemo-Pharma Laboratories Inc.
Debt-to-Equity Ratio 48.02 327.89 Chemo-Pharma Laboratories Inc.
PEG Ratio 0.42 4.61 Chemo-Pharma Laboratories Inc.
EV/EBITDA 13.60 12.91 Ashok Leyland Ltd.
Profit Margin (TTM) 6.53% 6.15% Chemo-Pharma Laboratories Inc.
Operating Margin (TTM) 11.52% 19.58% Ashok Leyland Ltd.
EBITDA Margin (TTM) 11.52% 19.58% Ashok Leyland Ltd.
Return on Equity 20.97% 19.61% Chemo-Pharma Laboratories Inc.
Return on Assets (TTM) 11.26% 3.80% Chemo-Pharma Laboratories Inc.
Free Cash Flow (TTM) $41.66M $-15.20B Chemo-Pharma Laboratories Inc.
Dividend Yield N/A 1.23% N/A
1-Year Return -5.34% 29.86% Ashok Leyland Ltd.
Price-to-Sales Ratio (TTM) 1.31 1.85 Chemo-Pharma Laboratories Inc.
Enterprise Value $5.40B $1,491.75B Ashok Leyland Ltd.
EV/Revenue Ratio 1.52 2.77 Chemo-Pharma Laboratories Inc.
Gross Profit Margin (TTM) 24.93% 39.20% Ashok Leyland Ltd.
Revenue per Share (TTM) $62 $91 Ashok Leyland Ltd.
Earnings per Share (Diluted) $5.81 $5.62 Chemo-Pharma Laboratories Inc.
Beta (Stock Volatility) 0.28 0.50 Chemo-Pharma Laboratories Inc.

Chemo-Pharma Laboratories Inc. vs Ashok Leyland Ltd. Stock Performance Analysis

Loading Price Chart...

CPL
ASHOKLEY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Chemo-Pharma Laboratories Inc.0.43%-0.20%-9.72%10.04%-11.06%-12.31%
Ashok Leyland Ltd.3.44%11.83%2.98%-8.72%-5.47%-14.70%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Chemo-Pharma Laboratories Inc.-5.34%232.23%82.57%325.71%1,271.09%1,271.09%
Ashok Leyland Ltd.29.86%85.46%161.85%208.73%1,137.42%1,632.39%

Performance & Financial Health Analysis: Chemo-Pharma Laboratories Inc. vs Ashok Leyland Ltd.

MetricCPLASHOKLEY
Market Information
Market Cap i₹4.62B₹997.97B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i97,70020,990,927
90 Day Avg. Volume i68,66129,019,554
Last Close₹70.50₹157.70
52 Week Range₹52.67 - ₹87.75₹114.96 - ₹215.42
% from 52W High-19.66%-26.79%
All-Time High₹128.00 (Jan 06, 2025)₹264.65 (Aug 26, 2024)
% from All-Time High-44.92%-40.41%
Growth Metrics
Quarterly Revenue Growth0.40%0.24%
Quarterly Earnings Growth0.41%0.07%
Financial Health
Profit Margin (TTM) i0.07%0.06%
Operating Margin (TTM) i0.12%0.20%
Return on Equity (TTM) i0.21%0.20%
Debt to Equity (MRQ) i48.02327.89
Cash & Liquidity
Book Value per Share (MRQ)₹28.58₹21.48
Cash per Share (MRQ)₹0.05₹16.17
Operating Cash Flow (TTM) i₹277.99M₹-29,041,000,000
Levered Free Cash Flow (TTM) i₹313.23M₹31.07B
Dividends
Last 12-Month Dividend Yield iN/A1.23%
Last 12-Month Dividend i₹0.00₹2.06

Valuation & Enterprise Metrics Analysis: Chemo-Pharma Laboratories Inc. vs Ashok Leyland Ltd.

MetricCPL (Apr 26, 2026)ASHOKLEY (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i13.2230.23
Forward P/E iN/A22.86
PEG Ratio i0.424.61
Price to Sales (TTM) i1.311.85
Price to Book (MRQ) i2.697.91
Market Capitalization
Market Capitalization i₹4.62B₹997.97B
Enterprise Value i₹5.40B₹1.49T
Enterprise Value Metrics
Enterprise to Revenue i1.522.77
Enterprise to EBITDA i13.6012.91
Risk & Other Metrics
Beta i0.280.50
Book Value per Share (MRQ) i₹28.58₹21.48

Financial Statements Comparison: Chemo-Pharma Laboratories Inc. vs Ashok Leyland Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCPL (2025)ASHOKLEY (2025)
Revenue/Sales i2.85B483.42B
Cost of Goods Sold i2.07B297.82B
COGS % of Revenue i72.6%61.6%
Gross Profit i778.98M185.60B
Gross Margin i27.4%38.4%
Research & Development iN/A1.59B
Operating Income (EBIT) i300.69M87.73B
Operating Margin i10.6%18.1%
EBITDA i353.29M101.77B
EBITDA Margin i12.4%21.1%
Pre-Tax Income i392.47M45.96B
Pre-Tax Income % of Revenue i13.8%9.5%
Income Tax i79.24M12.14B
Income Tax % of Revenue i2.8%2.5%
Net Income (Profit) i313.23M33.83B
Profit Margin i11.0%7.0%

Balance Sheet & Liquidity Metrics

MetricCPL (2025)ASHOKLEY (2025)
Cash & Equivalents i12.05M65.45B
Total Current Assets i2.51B342.40B
Total Current Assets % of Revenue i88.1%70.8%
Total Current Liabilities i1.17B265.51B
Total Current Liabilities % of Revenue i41.2%54.9%
Long-Term Debt i109.50M365.68B
Long-Term Debt % of Revenue i3.8%75.6%
Total Shareholders Equity i1.49B158.45B
Retained Earnings i1.08B63.58B
Retained Earnings % of Revenue i37.9%13.2%
Property, Plant & Equipment i48.61M319.40M

Cash Flow Statement Comparison

MetricCPL (2025)ASHOKLEY (2025)
Operating Cash Flow i277.99M-29.04B
Operating Cash Flow % of Revenue i9.8%-6.0%
Capital Expenditures i-47.82M-15.99B
Free Cash Flow i41.66M-15.20B
FCF Margin i1.5%-3.1%
Debt Repayment i-359.80M-336.33B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCPLASHOKLEY
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i60.18M5.87B
Float Shares i17.41M3.38B
% Held by Insiders i69.98%40.14%
% Held by Institutions i0.00%25.15%
% Held by Public i30.02%34.71%

Dividend Analysis & Yield Comparison: Chemo-Pharma Laboratories Inc. vs Ashok Leyland Ltd.

MetricCPLASHOKLEY
Last 12-Month Dividend i₹0.00₹2.06
Last 12-Month Dividend Yield iN/A1.23%
3-Year Avg Annual Dividend i₹0.00₹2.35
3-Year Avg Dividend Yield iN/A0.96%
3-Year Total Dividends i₹0.00₹7.05
Ex-Dividend DateN/ANov 18, 2025